NCT07164560 2026-03-17
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Recruiting
Clinical Trials
228 trialsNCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT04926285 2026-03-16
VEN-OM
University of Illinois at Chicago
Phase 1 Completed
NCT07137494 2026-03-16
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05748197 2026-03-10
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07257419 2026-03-10
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT06508138 2026-03-06
J21112LINKED
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Enrolling by invitation
NCT06321484 2026-03-04
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06868433 2026-03-04
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
Phase 1 Recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT06863259 2026-02-18
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT07113691 2026-02-17
TIARA
Yale University
Phase 1 Recruiting
NCT03029338 2026-02-11
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
NCT00709033 2026-01-30
ATECRAB
Baylor College of Medicine
Phase 1 Completed
NCT05184816 2026-01-30
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06193174 2026-01-22
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
Phase 1 Terminated
NCT06768476 2026-01-16
AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT07343934 2026-01-15
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
Phase 1 Not yet recruiting
NCT05544968 2026-01-12
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07309900 2026-01-12
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Recruiting
NCT07331064 2026-01-09
GABRIEL
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07316920 2026-01-06
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT01853631 2026-01-05
SAGAN
Baylor College of Medicine
Phase 1 Recruiting
NCT05098613 2025-12-24
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
University of Colorado, Denver
Phase 1 Recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT05564650 2025-12-08
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
Phase 1 Active not recruiting
NCT06649227 2025-12-05
CARLA-M19
University Hospital, Lille
Phase 1 Recruiting
NCT01840566 2025-12-03
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT05010005 2025-12-03
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06824701 2025-12-03
TARZAN
University of Utah
Phase 1 Recruiting
NCT06295549 2025-12-01
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Terminated
NCT02379520 2025-11-28
HESTIA
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06559189 2025-11-28
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
University of Colorado, Denver
Phase 1 Recruiting
NCT07003555 2025-11-26
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT07003568 2025-11-26
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Beijing GoBroad Hospital
Phase 1 Recruiting
NCT05768880 2025-11-20
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT06156410 2025-11-14
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT05010564 2025-11-13
TRICAR-ALL
Baylor College of Medicine
Phase 1 Recruiting
NCT05574114 2025-11-04
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT00368082 2025-10-31
TGF-beta
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01582191 2025-10-27
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02668770 2025-10-23
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05366179 2025-10-20
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
NCT04678336 2025-10-15
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Phase 1 Terminated
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04666649 2025-10-07
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
University of Maryland, Baltimore
Phase 1 Completed